Atovaquone/Proguanil and Zoster Vaccines Reduce Alzheimer's Risk: A Role for *Toxoplasma gondii?*

Ariel Israel[1,2]* MD, PhD, Abraham Weizman MD[3], Sarah Israel MD[4], Shai Ashkenazi MD, MSc[5,6], Shlomo Vinker MD, MHA[1], Eli Magen MD[7], Eugene Merzon MD, MPH[1,5]

Affiliations:

[1] Leumit Research Institute, Leumit Health Services, 23 Sprinzak St., Tel Aviv 6473817, Israel

[2] Department of Epidemiology and Preventive Medicine, School of Public Health, Faculty of Medical & Health Sciences, Tel Aviv University; Ramat Aviv, Tel Aviv 6997801, Israel

[3] Research Unit, Geha Mental Health Center, Felsenstein Medical Research Center, and Sagol School of Neurosciences, Faculty of Medical & Health Sciences, Tel Aviv University, 6997801, Israel

[4] Department of Clinical Microbiology and Infectious Diseases, Hadassah-Hebrew University Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, P.O. Box 12000, Jerusalem 9112001, Israel

[5] Adelson School of Medicine, Ariel University, Ariel 40700, Israel

[6] Department of Infectious Diseases, Schneider Children's Medical Center, 14 Kaplan St., Petah Tikva 4920235, Israel

[7] Medicine A Department, Assuta Ashdod University Medical Center, Ben Gurion University of the Negev, Derech HaRofe 7, Ashdod 7747629, Israel

Corresponding author:

Ariel Israel, MD, PhD

Leumit Research Institute

Leumit Health Services

23 Sprinzak St., Tel Aviv 6473817, Israel

Email: **aisrael@leumit.co.il**

Structured Abstract

INTRODUCTION: Identifying modifiable risk factors for Alzheimer's disease (AD) may provide insights into its etiology and inform prevention strategies.

METHODS: We analyzed 9,124 AD patients and 18,248 matched controls from a national cohort (2004–2024). Logistic regression, adjusted for age, gender, socioeconomic status, and comorbidities, identified medications tied to significant AD risk reduction (OR<0.5, FDR<0.05) for the decade following their uptake. Findings were validated in TriNetX (120M U.S. patients) using propensity score-matched Cox models for dementia hazard ratios (HR).

RESULTS: Atovaquone/proguanil (Ato/Pro) use was associated with lower AD risk (OR 0.36 [95% CI, 0.20–0.61]; HR 0.43 [95% CI, 0.35–0.53]), as were both varicella-zoster virus (VZV) vaccines (OR 0.16–0.37). *Toxoplasma gondii* seropositivity increased AD risk (HR 2.43, p=0.001).

DISCUSSION: Ato/Pro and VZV vaccines were AD-protective, with Ato/Pro's effect strongest in VZV-unvaccinated patients, supporting a hypothesis that latent *T. gondii* infection, reactivated by herpesvirus superinfection, may drive AD pathogenesis.

Abbreviations

AD: Alzheimer's Disease

Ato/Pro: Atovaquone/Proguanil

aOR: adjusted Odds Ratio

BBB: Blood-brain barrier

BMI: Body Mass Index

BP: Blood pressure

CNS: Central nervous system

COX-2: Cyclooxygenase-2

EHR: Electronic health records

FDR: False Discovery Rate

HCO: Healthcare organizations

HR: Hazards Ratio

ICD: International Classification of Diseases

IM: Intramuscular

LHS: Leumit Health Services

OR: Odds Ratio

PO: Per os

PSM: Propensity score matching

SES: Socioeconomic status

SMD: Standardized Mean Difference

T3: Triiodothyronine

1. Background

Alzheimer's disease (AD) is the most common cause of dementia, characterized by progressive cognitive decline and memory impairment. Globally, over 50 million individuals are affected by dementia, with AD accounting for 60-70% of these cases. This prevalence is projected to triple by 2050, reaching an estimated 152 million cases.[1]

The etiology of AD is multifactorial, involving both genetic and environmental factors. Approximately 70% of the risk can be attributed to genetics, notably the presence of the apolipoprotein E ε4 allele.[2] However, modifiable risk factors also play a significant role. Epidemiological studies have identified associations between AD and various factors, including hypertension, lifestyle, and cerebrovascular diseases. Conversely, protective factors such as higher educational attainment, cognitive engagement, and regular physical activity have been linked to a reduced risk of AD. [3] AD is pathologically characterized by the accumulation of amyloid-beta plaques and neurofibrillary tangles, leading to synaptic dysfunction and neuronal loss. Emerging evidence suggests that pathogen-induced neuroinflammation may exacerbate these pathological features, as infections can trigger chronic inflammatory responses in the brain, potentially accelerating AD progression.[4]

Recent research has explored the potential protective effects of vaccinations against AD. Immunizations, notably VZV vaccines, have been associated with a decreased risk of developing AD[5]. The proposed mechanisms include the enhancement of the immune system's ability to combat infections that may contribute to neuroinflammation and subsequent neurodegeneration.[6] Vaccination may also modulate immune responses that affect amyloid-beta clearance, reducing AD pathology.

The role of infections in AD pathogenesis and other neurodegenerative processes has garnered increasing attention. Several microbial taxa, including *Porphyromonas gingivalis[7]*, and herpesviruses[8,9], have been implicated in AD pathology through inflammatory and neurotoxic mechanisms. Moreover, antibodies against *Toxoplasma gondii*, a common parasitic infection, have been found at higher rates in individuals with neuropsychiatric disorders such as schizophrenia[10–12], and emerging evidence suggests a possible link to AD[12–14]. Chronic infections may contribute to sustained neuroinflammation, leading to neuronal damage,

synaptic dysfunction, and cognitive decline. Understanding the interplay between the microbiome, chronic infections, and neurodegeneration is critical for identifying novel preventive and therapeutic strategies for AD.[15]

In this study, we leveraged electronic health records (EHRs) from a national health organization in Israel to systematically investigate whether individuals who developed AD over the past two decades exhibited distinct patterns of previous medication use. Identifying significant reductions in AD occurrence among patients who had received prior antimicrobial treatments may provide insights into the role of targeted microorganisms in the pathogenic processes leading to AD development.

2. Methods

2.1 Study design

The first stage of this research was conducted as a retrospective cohort study in Leumit Health Services (LHS), one of the four nationwide health providers in Israel, providing comprehensive healthcare services to approximately 730,000 members. All Israeli citizens are entitled for comprehensive health insurance and receive a standardized package of health services and medications, as defined by the national "Health Basket" committee. LHS operates a centralized EHR system, with over two decades of meticulously maintained information on patient demographics, medical diagnoses, healthcare encounters, laboratory test results, and records of prescribed and purchased medications. Diagnoses are documented during medical encounters by the treating physicians using the International Classification of Diseases (ICD). Diagnoses can be marked as chronic when they pertain to a chronic condition, and these can be updated or closed by the treating physicians during subsequent patient encounters. The reliability of these chronic diagnosis records in our registry has been previously validated, demonstrating high accuracy.[16]

Eligibility included all LHS members with active membership between 2003 and 2024. Data were extracted from the LHS central data warehouse, covering diagnoses, laboratory test results, and medication purchases up to December 31, 2024. Structured query language (SQL) and Python scripts automated data

retrieval. Socioeconomic status was determined using geocoded residential addresses, classified on a scale of 1 (lowest) to 20 (highest) based on the Points Location Intelligence® database, which strongly correlates with official socioeconomic indicators. Geodemographic classification of the general population, Ultra-Orthodox Jewish, and Arab communities was performed using validated methodologies from prior studies.

2.2 LHS cohort definition

The study included AD patients diagnosed between ages 40 and 89, matched 2:1 with controls who had no dementia diagnosis. To minimize misclassification, individuals with cerebrovascular accident, schizophrenia, Down syndrome, or Parkinson's disease were excluded. AD cases were identified based on ICD-10 "F00" or ICD-9 "331" codes, with the earliest recorded diagnosis as the index date. Controls were matched to cases by gender, ethnic group (general population, Ultra-Orthodox, or Arab), socioeconomic status, and year of LHS enrollment. Matching prioritized individuals with the closest birth date to the AD patient, ensuring no duplication.

2.3 TriNetX Validation Cohort

Validation analyses were conducted using TriNetX, a federated research network with EHR data from 69 US healthcare organizations and over 120 million patients. The validation cohorts included individuals aged 65 with no prior dementia diagnosis. Cases were defined as those who had purchased the medication of interest, with controls selected from those who had not. Propensity score matching (PSM) was applied to balance age, ethnicity, race, smoking status, diabetes diagnosis, BMI, and HbA1c levels at medication initiation. Dementia incidence was assessed using Cox proportional hazards models, based on the combined occurrence of ICD-10 codes G30 (Alzheimer's disease) or F03 (unspecified dementia). Follow-up began 30 days post-index date with no predefined end limit. P-values were calculated using the log-rank test. Using the same methodology, we compared dementia incidence in individuals with past *T. gondii*-positive IgG or IgM serology vs. those with negative serology.

2.4 Data processing

Data from LHS were extracted from EHRs and processed using Python 3.11 scripts and T-SQL queries developed by the Leumit Research Institute. Patient identifiers were removed and replaced with study-specific codes to ensure anonymity. Medication use was assessed based on purchase records up to 10 years before the index date, classified by Anatomical Therapeutic Chemical (ATC) codes.

2.5 Statistical analyses

Analyses of LHS data were conducted using R version 4.4. Fisher's exact test was used for categorical variables and two-tailed t-tests for continuous variables. Conditional logistic regression models assessed associations between AD and medication use, adjusting for age, gender, smoking status, socioeconomic status, physician visits, pregnancy history, and health worker status.

2.6 Ethics Statement

Ethics approval was granted by the Leumit Health Services Institutional Review Board (LEU-0001-24), with a waiver of informed consent due to retrospective, anonymized data analysis.

3. Results

3.1 The study cohort

Table 1 summarizes the demographic and clinical characteristics of 9,124 AD patients and 18,248 controls in the LHS cohort. Due to the matching process, age and gender distributions were very similar (60.7% female, mean age 76.8 ± 8.0 years). AD patients had lower weight (71.5 ± 15.0 vs. 74.3 ± 15.1 kg), height (161 ± 12 vs. 162 ± 10 cm), and BMI. They were more likely to be smokers (OR 1.14 [95% CI, 1.09-1.20]) and had a higher prevalence of diabetes (OR 1.32 [95% CI, 1.25-1.39]), with elevated fasting glucose and hemoglobin A1c levels.

Notable laboratory differences included a higher proportion of AD patients with free T3 levels <3.5 pmol/L (OR 1.42 [95% CI, 1.28-1.58]) or severe vitamin D deficiency of <10 ng/mL (OR 1.32 [95% CI, 1.22-1.44]). Folic acid levels showed a bimodal distribution, with AD patients being more likely to have both

deficiency (<2.8 ng/mL, OR 1.48 [95% CI, 1.32-1.65]) and excess (>17 ng/mL, OR 1.30 [95% CI, 1.17-1.43]). Although mean ALT levels were comparable, AD patients had a higher prevalence of very low ALT (<8 U/L, OR 1.83 [95% CI, 1.62-2.07]).

3.2 Medication use associated with the risk of AD occurrence

Medication use over the past decade was systematically assessed for associations with AD risk using Fisher's exact test. Table 2 presents the three medications that met the criteria of OR <0.5 and FDR <5% (Benjamini-Hochberg correction). The two VZV vaccines were significantly associated with lower AD risk: the recombinant VZV vaccine (OR 0.16 [95% CI, 0.05-0.40]) and the live attenuated VZV vaccine (OR 0.37 [95% CI, 0.26-0.52]). Additionally, we observed a significant reduction in AD risk with Atovaquone/Proguanil (Ato/Pro) use, an antiprotozoal used for malaria prophylaxis (OR 0.36 [95% CI, 0.20-0.61]). This combination drug inhibits protozoal mitochondrial function and disrupts folate metabolism.

To further assess the independent effect of each medication on AD risk, we performed an adjusted multivariable regression analysis incorporating these three medications along with potential confounders. The associations remained robust, with adjusted odds ratios and p-values presented in the two rightmost columns of Table 2.

3.3 Validation in the US based trinetX collaborative network.

To validate these associations, we analyzed data from the U.S. TriNetX global network, which integrates EHRs from over 69 healthcare organizations, covering more than 120 million patients.

Results are summarized in Table 3, with selected comparisons visualized as cumulative incidence plots in Figure 1 (subplot letters are listed in the first column of Table 3). Each comparison included individuals with medication purchase recorded at either age 65 or 70 and no prior dementia diagnosis, using the purchase date as the index date. Groups were matched via propensity score matching for age, gender, ethnicity/race, diabetes status, BMI, and smoking status. In the first comparison, we analyzed two groups of 15,890 individuals aged 65 at the index date, with the first group having prior Ato/Pro use. Consistent with our national cohort findings, Ato/Pro use was associated with a significantly reduced AD risk (HR 0.43 [95% CI, 0.34-0.53], p <0.0001).

To assess whether this association persisted at an older age, we repeated the analysis for individuals with a medication purchase at age 70 (Fig. 1A). Despite increased mortality risk at this age, Ato/Pro use remained significantly associated with lower AD risk (HR 0.59 [95% CI, 0.51-0.68], p <0.0001).

To assess whether *T. gondii*, a parasite eliminated by Ato/Pro, is linked to dementia, we analyzed individuals under 85 years old with a prior *T. gondii* IgG or IgM test. We compared 1,456 individuals with positive serology with a matched group of individuals with negative serology and found a significantly higher incidence of dementia in the *T. gondii* positive group (HR 2.43, p=0.001; Fig. 1B).

We further examined whether VZV vaccination influenced the protective effect of Ato/Pro by stratifying individuals aged ≥70 based on their vaccination status. Among unvaccinated individuals (no prior VZV vaccine purchase), Ato/Pro use was associated with a greater and more significant reduction in AD risk (HR 0.51 [95% CI, 0.43–0.59]; Fig. 1C) compared to vaccinated individuals, who had received a VZV vaccine before the index date (HR 0.71 [95% CI, 0.59–0.85]; Fig. 1D). These findings suggest that Ato/Pro's protective effect against AD is stronger in individuals who had not received a VZV vaccine.

4 Discussion

This study identifies a novel association between Ato/Pro use and a reduced risk of AD. Conducted within a national health provider over a 20-year period, our large-scale retrospective analysis included 9,124 AD patients and 18,248 matched controls. The findings demonstrate a strong, statistically significant inverse association between prior Ato/Pro use and AD risk, suggesting a previously unrecognized protective factor against AD. Our study also confirmed the protective effect of the attenuated and recombinant VZV vaccines on AD.

To strengthen these observations, we independently validated the association in TriNetX, a U.S. global network with EHR data from over 120 million patients. Using established analytical frameworks, our findings remained consistent and reproducible, reinforcing the robustness of Ato/Pro's protective effect. Furthermore, *T.*

gondii seropositivity was significantly associated with AD occurrence, supporting the hypothesis that Ato/Pro's effect is mediated by *T. gondii* elimination.

Further analysis in TriNetX suggested that VZV vaccination influences Ato/Pro's protective effect, as the reduction in AD risk associated with Ato/Pro was more pronounced in VZV-unvaccinated individuals compared to those who had received a Zoster vaccine.

Based on our findings, we propose that latent *T. gondii* may contribute to AD pathogenesis. Specifically, we hypothesize that herpesvirus infection may trigger *T. gondii* reactivation, leading to neuroinflammation that drives AD pathology in genetically or immunologically susceptible individuals.

4.1 Toxoplasma gondii

Toxoplasma gondii is a ubiquitous protozoan parasite commonly found in the environment, with humans frequently acquiring asymptomatic, lifelong infections. While generally latent, *T. gondii* has been implicated in a range of neurological and psychiatric disorders[17,18], including schizophrenia[11], depression[19], and epilepsy[20]. Epidemiological studies have reported associations between *T. gondii* seropositivity and an increased risk of neuropsychiatric conditions, raising the possibility that chronic infection may contribute to neuroinflammation and progressive neuronal damage.

Findings on the association between *T. gondii* and AD have been inconsistent. While some cohorts found no significant link[21], recent cohort studies reported significant associations between *T. gondii* infection and dementia risk.[13,14] Additionally, an NHANES analysis found *T. gondii* seropositivity correlated with lower cognitive function scores, further suggesting neurological impacts of chronic infection[22].

Since *T. gondii* shares mitochondrial and folate metabolism pathways with other protozoa, Atovaquone is effective against it and is used with pyrimethamine as a DHFR inhibitor in toxoplasmosis treatment.[23]

Our systematic screening revealed significant AD protection also from both varicella zoster vaccines, likely by preventing herpesvirus infections in neurons, prompting a hypothesis linking herpesvirus reactivation, *T. gondii*, and AD pathology. We propose that in susceptible individuals, herpesvirus infection triggers reactivation of latent *T. gondii*, releasing bradyzoites that could then spread to adjacent neurons, inducing

chronic neuroinflammation contributing to amyloid plaques and neurodegeneration. This is supported by Ato/Pro reducing AD risk much more strongly in patients who had not been vaccinated for VZV (HR=0.51, P<0.0001), suggesting both *T. gondii* and herpesvirus (likely VZV) drive pathogenesis. Herpesvirus signatures detected across multiple AD cohorts reinforce this model.[9]

Neuronal cells, being quiescent and metabolically constrained, severely limit *Toxoplasma gondii*'s ability to replicate. Consequently, primary infection is typically contained within the CNS through an immune response that includes microglial activation and cytokine production. This response forces the parasite into its dormant bradyzoite stage, allowing *T. gondii* to evade immune surveillance and persist within host cells. Herpesvirus superinfection of *T. gondii*-harboring cells may disrupt this equilibrium. Viral replication-induced cytolysis can lead to the lysis of infected cells, releasing *T. gondii* into the extracellular space. The resulting neuroinflammatory response—characterized by cytokine release and increased blood-brain barrier (BBB) permeability—may facilitate further invasion of the parasite into adjacent neuronal and glial cells. This cascade of events could amplify neuroinflammation, neuronal damage, and neurodegeneration, ultimately contributing to AD pathology.

4.2 Liver Dysfunction and Immune Dysregulation

A significant proportion of AD patients from the LHS cohort exhibited very low alanine aminotransferase (ALT) levels, suggestive of hepatic dysfunction. The liver plays a key role in immune surveillance and pathogen clearance, filtering pathogens via Kupffer cells, natural killer (NK) cells, and T-cell responses. It also produces complement proteins and cytokines essential for controlling *T. gondii* replication. Interferon-gamma (IFN-γ), in particular, is crucial for host defense, and reduced hepatic cytokine production can impair parasite containment, increasing systemic spread and neuroinvasion. Based on observed associations in LHS, we hypothesize that liver dysfunction due to frailty, hepatitis, or alcoholism may further compromise these protective mechanisms, enabling *T. gondii* dissemination.

Immune dysregulation in AD patients was also evident in the LHS cohort, with significant reductions in key immune regulators, including vitamin D, T3, and folic acid. The bimodal distribution of folic acid suggests

that both deficiency, which can impair immune function, and excessive supplementation, which may promote *T. gondii* replication via its reliance on folic acid metabolism, may influence parasite invasion.

4.3 Conclusion

This large-scale, retrospective study, conducted over 20 years within a national health provider, is the first to identify a strong protective association between Ato/Pro and AD. Validation in the TriNetX U.S. network, encompassing over 120 million patients, reinforces the generalizability of these findings. The persistence of risk reduction for over a decade post-treatment in both Israeli and American cohorts, alongside increased *T. gondii* seropositivity in AD patients, strongly suggests a link between toxoplasmosis elimination and AD protection. While causality cannot be definitively established, the consistent temporal associations across two large cohorts provide compelling support for the protective effect of Ato/Pro, with *T. gondii* involvement in AD pathogenesis being the most plausible explanation. Moreover, with Ato/Pro's protective effect stronger in VZV-unvaccinated patients, we propose a unifying hypothesis wherein latent *T. gondii* infection, reactivated by herpesvirus infection in the context of immune dysfunction, impaired liver function, and neuroinflammation, ultimately drives AD. Future studies should further explore this mechanism and evaluate targeted interventions. Our findings suggest that controlled *T. gondii* elimination through antiprotozoals, potentially combined with agents that mitigate inflammation and prevent apoptosis in infected cells, such as selective or preferential COX-2 inhibitors, may represent a novel therapeutic avenue. Randomized controlled trials are needed to rigorously test this hypothesis and assess its clinical implications.

.

References

[1]   Contador I, Buch-Vicente B, del Ser T, Llamas-Velasco S, Villarejo-Galende A, Benito-León J, et al. Charting Alzheimer's Disease and Dementia: Epidemiological Insights, Risk Factors and Prevention Pathways. J Clin Med 2024;13:4100. https://doi.org/10.3390/jcm13144100.

[2]   Silva MVF, Loures C de MG, Alves LCV, de Souza LC, Borges KBG, Carvalho M das G. Alzheimer's disease: risk factors and potentially protective measures. J Biomed Sci 2019;26:33. https://doi.org/10.1186/s12929-019-0524-y.

[3]   Qiu C, Kivipelto M, von Strauss E. Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci 2009;11:111–28. https://doi.org/10.31887/DCNS.2009.11.2/cqiu.

[4]   Hensley K. Neuroinflammation in Alzheimer's Disease: Mechanisms, Pathologic Consequences, and Potential for Therapeutic Manipulation. Journal of Alzheimer's Disease 2010;21:1–14. https://doi.org/10.3233/JAD-2010-1414.

[5]   Taquet M, Dercon Q, Todd JA, Harrison PJ. The recombinant shingles vaccine is associated with lower risk of dementia. Nat Med 2024;30:2777–81. https://doi.org/10.1038/s41591-024-03201-5.

[6]   Ukraintseva S, Yashkin AP, Akushevich I, Arbeev K, Duan H, Gorbunova G, et al. Associations of infections and vaccines with Alzheimer's disease point to a role of compromised immunity rather than specific pathogen in AD. Exp Gerontol 2024;190:112411. https://doi.org/10.1016/j.exger.2024.112411.

[7]   Dominy SS, Lynch C, Ermini F, Benedyk M, Marczyk A, Konradi A, et al. *Porphyromonas gingivalis* in Alzheimer's disease brains: Evidence for disease causation and treatment with small-molecule inhibitors. Sci Adv 2019;5. https://doi.org/10.1126/sciadv.aau3333.

[8]   Piotrowski SL, Tucker A, Jacobson S. The elusive role of herpesviruses in Alzheimer's disease: current evidence and future directions. NeuroImmune Pharmacology and Therapeutics 2023;2:253–66. https://doi.org/10.1515/nipt-2023-0011.

[9] Readhead B, Haure-Mirande J-V, Funk CC, Richards MA, Shannon P, Haroutunian V, et al. Multiscale Analysis of Independent Alzheimer's Cohorts Finds Disruption of Molecular, Genetic, and Clinical Networks by Human Herpesvirus. Neuron 2018;99:64-82.e7. https://doi.org/10.1016/j.neuron.2018.05.023.

[10] Sutterland AL, Fond G, Kuin A, Koeter MWJ, Lutter R, van Gool T, et al. Beyond the association. Toxoplasma gondii in schizophrenia, bipolar disorder, and addiction: systematic review and meta☐analysis. Acta Psychiatr Scand 2015;132:161–79. https://doi.org/10.1111/acps.12423.

[11] Torrey EF, Bartko JJ, Yolken RH. Toxoplasma gondii and Other Risk Factors for Schizophrenia: An Update. Schizophr Bull 2012;38:642–7. https://doi.org/10.1093/schbul/sbs043.

[12] Kusbeci OY, Miman O, Yaman M, Aktepe OC, Yazar S. Could Toxoplasma gondii Have any Role in Alzheimer Disease? Alzheimer Dis Assoc Disord 2011;25:1–3. https://doi.org/10.1097/WAD.0b013e3181f73bc2.

[13] Yang H-Y, Chien W-C, Chung C-H, Su R-Y, Lai C-Y, Yang C-C, et al. Risk of dementia in patients with toxoplasmosis: a nationwide, population-based cohort study in Taiwan. Parasit Vectors 2021;14:435. https://doi.org/10.1186/s13071-021-04928-7.

[14] Wang J, Lin P, Li D, Yang B, Wang J, Feng M, et al. Analysis of the Correlation Between Toxoplasma gondii Seropositivity and Alzheimer's Disease. Pathogens 2024;13:1021. https://doi.org/10.3390/pathogens13111021.

[15] Lathe R, Schultek NM, Balin BJ, Ehrlich GD, Auber LA, Perry G, et al. Establishment of a consensus protocol to explore the brain pathobiome in patients with mild cognitive impairment and Alzheimer's disease. Alzheimer's & Dementia 2023;19:5209–31. https://doi.org/10.1002/alz.13076.

[16] Israel A, Merzon E, Schäffer AA, Shenhar Y, Green I, Golan-Cohen A, et al. Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection: test negative design study. The BMJ 2021;375:e067873. https://doi.org/10.1136/bmj-2021-067873.

[17] Flegr J. Effects of Toxoplasma on Human Behavior. Schizophr Bull 2007;33:757–60. https://doi.org/10.1093/schbul/sbl074.

[18] Henriquez SA, Brett R, Alexander J, Pratt J, Roberts CW. Neuropsychiatric Disease and <i>Toxoplasma gondii</i> Infection. Neuroimmunomodulation 2009;16:122–33. https://doi.org/10.1159/000180267.

[19] Hlaváčová J, Flegr J, Fiurašková K, Kaňková Š. Relationship between Latent Toxoplasmosis and Depression in Clients of a Center for Assisted Reproduction. Pathogens 2021;10:1052. https://doi.org/10.3390/pathogens10081052.

[20] Ngoungou EB, Bhalla D, Nzoghe A, Dardé M-L, Preux P-M. Toxoplasmosis and Epilepsy — Systematic Review and Meta Analysis. PLoS Negl Trop Dis 2015;9:e0003525. https://doi.org/10.1371/journal.pntd.0003525.

[21] Wyman CP, Gale SD, Hedges-Muncy A, Erickson LD, Wilson E, Hedges DW. Association between Toxoplasma gondii seropositivity and memory function in nondemented older adults. Neurobiol Aging 2017;53:76–82. https://doi.org/10.1016/j.neurobiolaging.2017.01.018.

[22] Wiener RC, Waters C, Bhandari R. The association of Toxoplasma gondii IgG and cognitive function scores: NHANES 2013–2014. Parasitol Int 2020;78:102123. https://doi.org/10.1016/j.parint.2020.102123.

[23] KOVACS J. Efficacy of atovaquone in treatment of toxoplasmosis in patients with AIDS. The Lancet 1992;340:637–8. https://doi.org/10.1016/0140-6736(92)92172-C.

Footnotes

Conflicts of interest: Authors declare that they have no competing interests.

Funding Sources: This study was funded internally by Leumit Research Institute.

Consent Statement: Ethics approval was granted by the Leumit Health Services Institutional Review Board (LEU-0001-24), with a waiver of informed consent due to retrospective, anonymized data analysis.

Keywords: Alzheimer's disease, atovaquone/proguanil, neuroinflammation, *Toxoplasma gondii*, Varicella zoster vaccines, herpesvirus

Author contributions:

Conceptualization: AI, EMe, Ema

Methodology: AI, Eme

Investigation: AI, SI, JS, Eme

Writing - original draft: AI

Writing - review & editing: AI, AW, SI, JS, SA, SV, EMa, EMe

Table 1. Demographic and clinical characteristics of the study cohort at index date

		AD N=9,124	Control N=18,248	P-value	Odds Ratio	SMD
Gender	Female	5,536 (60.7 %)	11,072 (60.7 %)	1.000	1	
	Male	3,588 (39.3 %)	7,176 (39.3 %)	1.000	1	
Age (years)		76.8 ± 8.0	76.7 ± 8.0	0.268		0.014
Age category	40-49	93 (1.02 %)	184 (1.01 %)	0.949	1.01 [0.78-1.31]	
	50-59	237 (2.60 %)	487 (2.67 %)	0.749	0.97 [0.83-1.14]	
	60-69	1,070 (11.73 %)	2,180 (11.95 %)	0.606	0.98 [0.90-1.06]	
	70-79	3,827 (41.94 %)	7,729 (42.36 %)	0.525	0.98 [0.93-1.03]	
	80-89	3,897 (42.71 %)	7,668 (42.02 %)	0.048	1.02 [1.01-1.15]	
Weight (kg)		71.5 ± 15.0	74.3 ± 15.1	<0.001		-0.189
	missing	73 (2.23 %)	2,280 (6.97 %)			
Height (cm)		161 ± 12	162 ± 10	<0.001		-0.093
	missing	122 (3.73 %)	3,248 (9.92 %)			
Body Mass Index (kg/m2)		27.8 ± 5.5	28.5 ± 5.2	<0.001		-0.131
	missing	1,775 (19.5 %)	2,672 (14.6 %)			
BP systolic (mmHg)		134 ± 24	135 ± 19	<0.001		-0.051
	missing	100 (1.10 %)	282 (1.55 %)			
BP diastolic (mmHg)		75.6 ± 10.1	76.0 ± 9.6	<0.001		-0.043
	missing	104 (1.14 %)	291 (1.59 %)			
Smoking status	Non-smoker	2,127 (23.6 %)	4,564 (25.4 %)	0.001	0.91 [0.85-0.96]	
	Past smoker	2,573 (28.5 %)	5,396 (30.0 %)	0.010	0.93 [0.88-0.98]	
	Smoker	4,320 (47.9 %)	7,997 (44.5 %)	<0.001	1.14 [1.09-1.20]	
	missing	104 (1.1 %)	291 (1.6 %)	0.003	0.71 [0.56-0.89]	
Diabetes Mellitus		3,335 (36.6 %)	5,545 (30.4 %)	<0.001	1.32 [1.25-1.39]	
eGFR MDRD (mL/min/1.73m2)		72.7 ± 26.8	72.1 ± 22.8	0.080		0.023
	missing	152 (1.67 %)	539 (2.95 %)			
Glucose (mg/dL)		114 ± 42	110 ± 31	<0.001		0.122
	missing	157 (1.72 %)	544 (2.98 %)			
Hemoglobin A1c (%)		6.32 ± 1.32	6.19 ± 1.02	<0.001		0.113
	missing	1,328 (14.6 %)	3,382 (18.5 %)			
Free T3 (pmol/L)		4.03 ± 1.01	4.16 ± 0.96	<0.001		-0.137
	< 3.5 pmol/L	760 (24.2 %)	1,134 (18.4 %)	<0.001	1.42 [1.28-1.58]	
	missing	6,006 (65.7 %)	12,112 (66.2 %)			
Vitamin D (ng/mL)		21.4 ± 11.0	22.4 ± 10.9	<0.001		-0.092
	< 10 ng/mL	1,067 (14.7 %)	1,761 (11.5 %)	<0.001	1.32 [1.22-1.44]	
	missing	1,891 (20.7 %)	3,027 (16.6 %)			
Folic Acid (ng/mL)		8.37 ± 8.37	8.28 ± 4.82	0.015		0.015
	< 2.8 ng/mL	590 (6.76 %)	783 (4.67 %)	<0.001	1.48 [1.32-1.65]	
	> 17 ng/mL	724 (8.30 %)	1,094 (6.53 %)	<0.001	1.30 [1.17-1.43]	
	missing	418 (4.57 %)	1,531 (8.37 %)			
ALT(GPT) (U/L)		19.2 ± 27.1	19.3 ± 17.9	0.903		-0.001
	< 8 U/L	534 (5.85 %)	592 (3.28 %)	<0.001	1.83 [1.62-2.07]	
	missing	19 (0.21 %)	231 (1.26 %)			

SMD: Standardized Mean Difference (Cohen's D)

Table 2. Comparison of medication purchases in the 10 years preceding the index date in the AD and control groups of the LHS cohort

Medication	AD N=9,124	Control N=18,248	Odds Ratio [95% CI]	adjusted Odds Ratio [95% CI]	adjusted p-value
Atovaquone + Proguanil (PO)	17 (0.19%)	94 (0.51%)	0.36 [0.20-0.61]	0.41 [0.24-0.69]	0.0008
Zoster, Purified antigen vaccine (IM)	5 (0.05%)	62 (0.34%)	0.16 [0.05-0.40]	0.20 [0.08-0.50]	0.0006
Zoster, Live attenuated vaccine (SC)	41 (0.45%)	218 (1.19%)	0.37 [0.26-0.52]	0.39 [0.28-0.55]	<0.0001

PO: Per Os; SC: Subcutaneous; IM: Intramuscular
Odds ratio were computed according to Fisher's exact tests performed on the matched cohort
Adjusted odds ratio and p-value, were computed according to a conditional logistic regression model which included all the listed medications and is adjusted for age (years), gender, smoking status, SES category, number of past physician visits, previous pregnancy, and health worker status

Table 3. Outcome Comparisons Studies in TriNetX U.S. cohort

Figure 1 subplot	Group case	Group control	Outcome	VZV vaccination status	Age	N found	N matched	HR	95% Confidence Interval	P-value
	Atovaquone treated	Any medication	Dementia		65	26,430	15,890	0.43	[0.34-0.53]	$4.5 \cdot 10^{-16}$
A	Atovaquone treated	Any medication	Dementia		70	29,980	19,637	0.59	[0.51-0.68]	$3.6 \cdot 10^{-13}$
B	Toxoplasma pos.	Toxoplasma neg.	Dementia		65	1443	1443	2.43	[1.39-4.25]	0.0013
C	Atovaquone treated	Any medication	Dementia	Unvaccinated	70	20,529	13,881	0.51	[0.43-0.59]	$8.8 \cdot 10^{-18}$
D	Atovaquone treated	Any medication	Dementia	Vaccinated	70	14,498	9258	0.71	[0.59-0.85]	0.00022

Cumulative incidence plots for selected comparisons are available as Figure 1

Figure 1: Cumulative incidence plots of dementia in TriNetX comparisons

VACCINATED = Zoster vaccine recipients